PMID- 24742768
OWN - NLM
STAT- MEDLINE
DCOM- 20150701
LR  - 20151119
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 19
IP  - 6
DP  - 2014 Nov
TI  - Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil 
      in pulmonary arterial hypertension (SITAR) study.
PG  - 550-7
LID - 10.1177/1074248414528066 [doi]
AB  - PURPOSE: Among phosphodiesterase type 5 inhibitors, tadalafil offers clinicians a 
      once-daily alternative to 3 times daily sildenafil for the treatment of pulmonary 
      arterial hypertension (PAH). This study assessed the safety and patient 
      satisfaction with conversion from sildenafil to tadalafil. METHODS: In this 
      multicenter, prospective, 6-month study, patients with PAH were instructed to 
      take their last dose of sildenafil in the evening and initiate tadalafil 40 mg/d 
      the next morning. Patients completed the Treatment Satisfaction Questionnaire for 
      Medication at baseline and 30, 90, and 180 days after transition to assess PAH 
      symptoms and patient satisfaction. Safety was assessed on the basis of recorded 
      adverse events (AEs). RESULTS: Of the 35 patients who met the study criteria, 56% 
      were receiving >/=2 PAH therapies. At the time of transition, the sildenafil dose 
      ranged from 40 to 300 mg/d, with 20% of the patients on >20 mg of sildenafil 3 
      times daily. Transition to tadalafil was generally well tolerated, and the 
      incidence of common AEs, except for myalgia, appeared to decrease over time on 
      tadalafil therapy. Five (14%) patients switched back to sildenafil. A greater 
      percentage of patients were satisfied than were dissatisfied after conversion to 
      tadalafil (55% vs 19% at 90 days), while 26% felt about the same degree of 
      satisfaction. Conversion to tadalafil resulted in significant improvement in 
      patient ratings of therapy convenience. CONCLUSIONS: Transition of patients from 
      sildenafil to tadalafil was usually well tolerated, with improved convenience and 
      may enhance treatment satisfaction.
CI  - (c) The Author(s) 2014.
FAU - Frantz, Robert P
AU  - Frantz RP
AD  - Division of Cardiovascular Diseases, College of Medicine, Mayo Clinic, Rochester, 
      MN, USA frantz.robert@mayo.edu.
FAU - Durst, Louise
AU  - Durst L
AD  - Mayo Clinic, Rochester, MN, USA.
FAU - Burger, Charles D
AU  - Burger CD
AD  - Division of Pulmonary Medicine, Mayo Clinic, Jacksonville, FL, USA.
FAU - Oudiz, Ronald J
AU  - Oudiz RJ
AD  - Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 
      Torrance, CA, USA.
FAU - Bourge, Robert C
AU  - Bourge RC
AD  - Cardiovascular Medicine, University of Alabama at Birmingham, Birmingham, AL, 
      USA.
FAU - Franco, Veronica
AU  - Franco V
AD  - Cardiovascular Medicine, Ohio State University Medical Center, Columbus, OH, USA.
FAU - Waxman, Aaron B
AU  - Waxman AB
AD  - Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
FAU - McDevitt, Susanne
AU  - McDevitt S
AD  - United Therapeutics Corporation, Research Triangle Park, NC, USA.
FAU - Walker, Susan
AU  - Walker S
AD  - United Therapeutics Corporation, Research Triangle Park, NC, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT01043627
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140417
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Carbolines)
RN  - 0 (Phosphodiesterase 5 Inhibitors)
RN  - 0 (Piperazines)
RN  - 0 (Purines)
RN  - 0 (Sulfonamides)
RN  - 0 (Vasodilator Agents)
RN  - 742SXX0ICT (Tadalafil)
RN  - BW9B0ZE037 (Sildenafil Citrate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antihypertensive Agents/adverse effects/*therapeutic use
MH  - Arterial Pressure/*drug effects
MH  - Carbolines/adverse effects/*therapeutic use
MH  - *Drug Substitution
MH  - Female
MH  - Humans
MH  - Hypertension, Pulmonary/diagnosis/*drug therapy/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Patient Satisfaction
MH  - Phosphodiesterase 5 Inhibitors/adverse effects/*therapeutic use
MH  - Piperazines/adverse effects/*therapeutic use
MH  - Prospective Studies
MH  - Pulmonary Artery/*drug effects/physiopathology
MH  - Purines/adverse effects/therapeutic use
MH  - Sildenafil Citrate
MH  - Sulfonamides/adverse effects/*therapeutic use
MH  - Surveys and Questionnaires
MH  - Tadalafil
MH  - Time Factors
MH  - Treatment Outcome
MH  - United States
MH  - Vasodilator Agents/adverse effects/*therapeutic use
MH  - Young Adult
OTO - NOTNLM
OT  - patient satisfaction
OT  - pulmonary arterial hypertension
OT  - sildenafil
OT  - switch
OT  - tadalafil
EDAT- 2014/04/20 06:00
MHDA- 2015/07/02 06:00
CRDT- 2014/04/19 06:00
PHST- 2014/04/19 06:00 [entrez]
PHST- 2014/04/20 06:00 [pubmed]
PHST- 2015/07/02 06:00 [medline]
AID - 1074248414528066 [pii]
AID - 10.1177/1074248414528066 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2014 Nov;19(6):550-7. doi: 10.1177/1074248414528066. 
      Epub 2014 Apr 17.